Miami, Florida — September 30, 2025 — Leads & Copy — MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) has completed its acquisition of SKNY Pharmaceuticals, Inc., adding $5 million in marketable securities and strengthening its financial position. The acquisition complements MIRA’s advancing programs, including Ketamir-2 and MIRA-55.
SKNY fulfilled all closing obligations as part of the transaction, contributing $5 million in marketable securities to MIRA, further strengthening the Company’s balance sheet.
Erez Aminov, CEO of MIRA, stated that the closing of the SKNY acquisition marks a pivotal milestone for MIRA, both financially and strategically. He added that the company is expanding its pipeline into obesity and nicotine addiction with SKNY-1, while continuing to advance Ketamir-2 through clinical development and progressing MIRA-55 as a novel approach to inflammatory and nociceptive pain. These programs position MIRA to address major unmet needs across some of the largest healthcare markets.
SKNY-1 is a differentiated oral drug candidate designed to modulate CB1, CB2, and MAO-B pathways to address energy storage, lipid metabolism, appetite, cravings, and reward without the psychiatric side effects that limited earlier CB1-targeting drugs. Preclinical findings include up to 30% reduction in body weight without muscle loss in validated animal models, marked modification of metabolic parameters, reversal of nicotine craving and high-calorie food cravings, and a favorable CNS safety profile compared with prior CB1-targeting agents.
Dr. Itzchak Angel, Chief Scientific Advisor at MIRA, commented that SKNY-1’s unique biased CB1 signaling and favorable CB2/MAO-B activity translate into robust and broad-spectrum efficacy across metabolic syndrome, obesity, and addiction models while addressing the safety limitations of earlier agents. He believes it has the potential to be best-in-class.
On September 22, 2025, MIRA announced favorable topline results from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial of Ketamir-2, its proprietary next-generation ketamine analog. The study demonstrated Ketamir-2 was safe and well tolerated across all dose levels, with predictable absorption, once-daily dosing potential, and no CNS side effects typically associated with ketamine. Preclinical studies further support Ketamir-2’s potential in neuropathic pain, depression, and PTSD.
MIRA-55, the Company’s oral pharmaceutical cannabis-derived candidate, has shown preclinical results in inflammatory and nociceptive pain comparable to morphine. Unlike opioids, MIRA-55 is designed to provide pain relief without addictive risk.
Obesity, metabolic disorders, nicotine addiction, neuropathic pain, nociceptive and inflammatory pain, depression, and post-traumatic stress disorder (PTSD) represent some of the largest and fastest-growing healthcare markets, each with high prevalence and substantial unmet medical need.
MIRA is directly addressing these areas through its pipeline: SKNY-1 for obesity and nicotine addiction, Ketamir-2 for neuropathic pain with potential in depression and PTSD, and MIRA-55 for inflammatory and nociceptive pain. Additional preclinical programs target cognitive impairment and related neuropsychiatric disorders.
These programs underscore MIRA’s strategy of advancing differentiated, non-opioid, and non-addictive therapeutic options aimed at improving patient outcomes in high-value markets.
Contact: Helga Moya, info@mirapharma.com, (786) 432-9792
Source: MIRA Pharmaceuticals, Inc.
